Literature DB >> 33839562

Mild encephalopathy with reversible splenial lesion: Description of nine cases and review of the literature.

Lina Grosset1, Hassan Hosseini2, Blanche Bapst3, Jérôme Hodel4, Laurent Cleret De Langavant5, Frédéric Faugeras6, Anne-Catherine Bachoud-Lévi7, Lilia Seddik8.   

Abstract

Mild encephalopathy/encephalitis with reversible splenial lesion (MERS) is a transient clinico-radiological syndrome characterized by non-specific encephalopathy and specific magnetic resonance imaging (MRI) pattern. MRI shows an ovoid lesion in the mid-splenium of the corpus callosum (SCC), with signal-intensity anomaly similar to stroke but vanishing within few weeks. Although there are a lot of child MERS cases descriptions, there are just a few adult-onset reported. Our goal is to provide a better clinical and radiological description of this entity. We reported nine adult-onset cases of MERS managed in our stroke unit between 2017 and 2019. The study of our adult series suggests that epilepsy and the context of an infection are very common in MERS. Adult cases show frequent focal neurological deficits and few encephalopathies compared to children. The measurement of very low ADC values in SCC lesion is a new radiological feature of MERS that should be systematically assessed in suspected cases to differentiate this complex syndrome from SCC strokes.
Copyright © 2021 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apparent diffusion coefficient; Encephalitis; Encephalopathy; Epilepsy; MERS

Year:  2021        PMID: 33839562     DOI: 10.1016/j.seizure.2021.03.032

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  1 in total

1.  Diffusion Restricted Lesions in the Splenium of the Corpus Callosum.

Authors:  Alex Förster; Paul Apfaltrer; Mansour Al-Zghloul; Holger Wenz; Angelika Alonso; Christoph Groden
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.